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Abstract
Development of anti-severe acute respiratory syndrome associated coronavirus (SARS-CoV) agents is pivotal to prevent 
the reemergence of the life-threatening disease, SARS. In this study, more than 200 extracts from Chinese medicinal 
herbs were evaluated for anti-SARS-CoV activities using a cell-based assay that measured SARS-CoV-induced 
cytopathogenic effect (CPE) in vitro on Vero E6 cells. Six herbal extracts, one each from Gentianae Radix (龍膽 lóng 
dǎn; the dried rhizome of Gentiana scabra), Dioscoreae Rhizoma (山藥 shān yào; the tuber of Dioscorea batatas), 
Cassiae Semen (決明子 jué míng zǐ; the dried seed of Cassia tora) and Loranthi Ramus (桑寄生 sāng jì shēng; the dried 
stem, with leaf of Taxillus chinensis) (designated as GSH, DBM, CTH and TCH, respectively), and two from Rhizoma 
Cibotii (狗脊 gǒu jǐ; the dried rhizome of Cibotium barometz) (designated as CBE and CBM), were found to be potent 
inhibitors of SARS-CoV at concentrations between 25 and 200 μg/ml. The concentrations of the six extracts needed 
to inhibit 50% of Vero E6 cell proliferation (CC50) and 50% of viral replication (EC50) were determined. The resulting 
selective index values (SI = CC50/EC50) of the most effective extracts CBE, GSH, DBM, CTH and TCH were > 59.4, > 
57.5, > 62.1, > 59.4, and > 92.9, respectively. Among these extracts, CBM and DBM also showed significant inhibition 
of SARS-CoV 3CL protease activity with IC50 values of 39 μg/ml and 44 μg/ml, respectively. Our findings suggest that 
these six herbal extracts may have potential as candidates for future development of anti-SARS therapeutics.
Abbreviations: SARS, severe acute respiratory syndrome; CoV, coronavirus; CPE, cytopathogenic effect; TCM, 
traditional Chinese medicine
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Introduction
Severe acute respiratory syndrome (SARS) is a 
highly infectious, life-threatening disease caused by a 
novel coronavirus, severe acute respiratory syndrome 
coronavirus (SARS-CoV) (Drosten et al., 2003; Ksiazek 
et al., 2003; Kuiken et al., 2003). In 2003, SARS 
spread quickly in over 25 countries and caused 8098 
probable SARS cases and 774 SARS-related deaths. 
Although various candidate drugs have subsequently 
been reported to attenuate the disease (Cinatl et al., 
2005; Hoever et al., 2005; Holmes, 2003), there are 
currently still no clinically approved or recommended 
antiviral drugs specific for SARS use. Currently, the 
most frequent treatment for SARS is antiviral and 
supportive treatment using a combination of ribavirin 
and corticosteroids (Peiris et al., 2003; So et al., 2003). 
However, ribavirin is only marginally effective against 
the SARS virus, and shows serious adverse side effects 
(Cinatl et al., 2003; Stroher et al., 2004).  Since the 
SARS outbreak, considerable effort has been put into 
antiviral research to evaluate drug candidates for anti-
SARS-CoV activity to prevent possible re-emergence 
of the disease (Wen et al., 2007; Wu et al., 2004). 
Notably, glycyrrhizin from licorice roots and a number 
of glycyrrhizin derivatives have been shown to possess 
demonstrable anti-SARS-CoV bioactivities (Hoever 
et al., 2005; Wu et al., 2004). And the non-steroidal 
anti-inflammatory drug, indomethacin, was also found 
to confer potent antiviral activity against SARS-CoV 
(Amici et al., 2006). A number of traditional herbal 
medicines have also been reported to possess antiviral 
activity against SARS-CoV (Chen et al., 2008; Li et al., 
2005; Lin et al., 2005; Ryu et al., 2010).
The SARS-CoV genome encodes various key 
protein molecules that may serve as  potential targets 
for chemotherapeutic inhibition of viral infection and 
replication (Lai, 2005; Stadler et al., 2003). These vital 
targets include: the spike protein (S), the SARS-CoV 
main protease (3CL protease), the NTPase/helicase, 
the RNA-dependent RNA polymerase, the membrane 
protein (M), the envelope protein (E), and the 
nucleocapsid phosphoprotein (N) and possibly other 
viral protein-mediated processes (De Clercq, 2004; 
Gallagher and Buchmeier, 2001; Groneberg et al., 
2005; Holmes, 2003; Kliger et al., 2005; Lai, 2005; 
Stadler et al., 2003). Anti-SARS-CoV agents that can 
inhibit SARS-CoV replication may be involved in 
inhibition of one or more of the above protein targets 
including SARS-CoV 3CL protease. This important 
protease regulates the proteolytic processing of replicase 
polypeptides into functional proteins, playing an 
essential role in viral replication (Chen et al., 2002; 
Kuo et al., 2004). SARS-CoV 3CL protease is thus an 
attractive target for drug candidates against SARS. 
In this study, we first investigated the effects of 
extracts of traditional Chinese medicinal (TCM) herbs 
on anti-SARS-CoV activity using a Vero E6 cell-based 
cytopathogenic effect (CPE) assay. The herbal extracts 
with anti-SARS-CoV activity shown by the CPE assay 
were subsequently evaluated for inhibition of SARS-
CoV replication using ELISA. These bioactive extracts 
were then further investigated for inhibition of SARS-
CoV 3CL protease activity. Our findings demonstrate 
that six previously unreported specific herbal extracts 
may have potential for use as drug targets for future 
development of anti-SARS therapeutics.
Materials and Methods
Preparation of extracts from traditional Chinese 
medicinal herbs
More than 50 traditional Chinese medicinal herbs 
were prepared and used as shown in Figure 1. Briefly, 
plant materials were ground into a powder, immersed in 
10-fold volume of water in a sonicator for 1 hour, and 
filtered. Three-fold volume of 95% ethanol was further 
added to the filtrate left for 1 hour and centrifuged at 
10000g for 20 minutes, at 4℃. The supernatant was 
rotor-evaporated and then freeze-dried to obtain the E 
fraction, and the 70% ethanol precipitated fraction was 
Figure 1. Schematic representation of different preparations of test 
herbal extracts. The E, W, M and H fractions from all tested plant 
materials were fractionated and dried as described in Materials and 
Methods.

Wen et al . / Journal of Traditional and Complementary Medicine 1 (2011) 
freeze-dried to obtain the W fraction. The previous 
residue was mixed with 5-fold volume of methanol, left 
for 1 hour, and filtered again to obtain two fractions, the 
filtrate  and the residue. The filtrate was rotor-
evaporated, and further freeze-dried to obtain the M 
fraction. The residue was then mixed with 5-fold 
volume of n-hexane in a sonicator for 1 hour, kept 
overnight, filtered, rotor-evaporated, and further freeze-
dried to obtain a filtrate (H). All plant materials were 
coded as the first letters of the name of the genus and 
species followed by the abbreviation for the preparative 
method. For example, the W, E, M and H extracts of 
Cibotium barometz  were abbreviated as CBW, CBE, 
CBM and CBH, respectively. 
Cytopathogenic effect of SARS-CoV on Vero E6 cells 
Eight wells were prepared to test each extract: three 
wells contained virus-infection only with no test extract 
(as positive control for CPE); three wells contained 
virus-infection with extract treatment; and two wells 
contained extract treatment only, without viral infection. 
In brief, Vero E6 cells (2 × 104/well) were cultured in 
96-well plates in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10 % fetal bovine serum 
(FBS) at 37℃ in an incubator with 5% CO2  for one 
day. When cells reached 80-90% confluence, the culture 
medium was removed and replenished with 100 μL 
DMEM supplemented with 2% FBS. Test cell cultures 
at≧90% confluence were treated with or without 
tested extracts in a DMEM + 2% FBS medium. Two 
hours later, test cells in 50 μL of culture medium were 
incubated with SARS-CoV (Hong Kong strain) at a dose 
of 100 TCID50 (50% tissue culture infectious doses) 
per well. The cytopathogenic morphology of cells was 
observed and evaluated at 72 hours post infection using 
inverted phase contrast microscopy.
Inhibition of SARS-CoV mediated CPE by the 
tested extracts was classified into three levels (+++, 
++, +) as previously reported (Tan et al., 2004). Cell 
cultures in which less than 25% of Vero E6 cells showed 
cytopathogenic morphology in response to SARS-CoV 
after treatment with extracts were scored as +++. Cell 
cultures in which 25-50% and 50-70% cells showed 
cytopathogenic morphology were scored as ++ and +, 
respectively.
Cytotoxicity of test extracts on Vero E6 Cells 
The assay protocol was as reported previously 
(Wen et al. ,  2007). Briefly, Vero E6 cells (2 × 
104/well) were cultured in 96-well plates in DMEM 
supplemented with 10% FBS at 37℃ in a 5% CO2 
incubator. After incubation for one day during which 
cultured cells reached 90% confluence, the culture 
medium was replenished with 100 μL fresh DMEM 
medium containing 2% FBS and test extracts at 
varying concentrations, were placed into microwells 
and incubated for 3 days. The test culture medium 
was then replenished with 100 μL fresh culture 
medium containing 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) at a concentration 
of 0.5 mg/mL per well for 4 hours. Optical density (OD) 
was then measured with a spectrophotometer at 570 nm. 
Survival of Vero E6 cells after treatment was calculated 
using the formula: viable cell number (%) = [OD570 (treated 
cells)]/OD570 (vehicle control cells)] × 100. The CC50 value was 
taken to be the test compound concentration at which 
cell viability was reduced by 50%.
Inhibition of viral replication in SARS-CoV-infected 
Vero E6 cells
The inhibitory effects of test extracts on SARS-CoV 
replication were measured as previously described (Wen 
et al., 2007). Briefly, after test extracts had been added 
to Vero E6 cells and incubated for 3 days with SARS-
CoV, the cells were gently rinsed with PBS three times 
and then fixed with 10% formalin for 5 minutes at room 
temperature. The 10% formalin was removed and the 
cells were fixed again in methanol/acetone (v/v, 1:1) 
solution for 5 minutes at room temperature. Cells were 
then blocked with 3% skim milk in PBS for 2 hours at 
room temperature, rinsed three times with PBS, and 
then incubated for 1 hour at 37℃ with 1:2,000 dilution 
of monoclonal antibody against the spike protein of 
SARS-CoV. All samples were then rinsed with three 
changes of PBS containing 0.05% Tween 20 (PBS-T 
buffer) followed by washing twice with fresh PBS at 
room temperature; and finally rinsed with 3% skim 
milk in PBS-T buffer. Cells were then incubated with a 
horseradish peroxidase-conjugated goat anti-mouse IgG 
for 30 minutes at room temperature. After rinsing three 
times with PBS-T buffer, a substrate solution containing 
o -phenylenediamine dihydrochloride, citrate buffer 
(pH 5.0), and hydrogen peroxide was added to each 
well. Plates were covered and gently shaken at room 
temperature for 10 minutes in the dark. The reaction was 
stopped by addition of 2 N sulfuric acid, and absorbance 
was read immediately at 492 nm on an ELISA reader. 
The EC50 value for each test compound was calculated 
from a linear regression plot of compound concentration 
versus OD492.
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SARS-CoV 3CL protease inhibition assay 
The gene encoding the SARS-CoV main protease 
was cloned from the whole viral genome by polymerase 
chain reaction (PCR) and primer insertion (forward 
primer 5′-GGTATTGAGGGTCGCAGTGGTTTTAGG
-3′ and reverse primer 5′-AGAGGAGAGTTAGAGCC
TTATTGGAAGGTAACACC-3′) into the pET32Xa/Lic 
vector as reported previously (Chen et al., 2002; Kuo 
et al., 2004).  The recombinant 3CL protease plasmid 
was then transformed into E. coli  JM109 competent 
cells that were streaked on a Luria–Bertani (LB) agar 
plate containing 100 μg/mL of ampicillin. The correct 
construct was subsequently transformed into E. coli 
BL21 host cells for expression of the His-tagged 
protein, which was then digested with FXa protease to 
remove the tag. The purified protein was confirmed by 
N-terminal sequencing and mass spectrometry analysis. 
The enzyme concentration used in all experiments was 
measured by the absorbance at 280 nm.
The  k ine t ic  measurements  were  per formed 
i n  a  s o l u t i o n  c o n t a i n i n g  2 0  m M  b i s [ ( 2 -
hydroxyethyl)amino]tris(hydroxymethyl)methane (pH 
7.0) at 25℃. Enhanced fluorescence resulting from 
cleavage of the fluorogenic substrate peptide (Dabcyl-
KTSAVLQ-SGFRKME-Edans) of SARS 3CL-protease 
was monitored on a fluorescence plate reader (538 nm 
emission, 355 nm excitation). The initial velocities of 
the inhibiting activities on 50 nM SARS 3CL-protease 
using 6 μM fluorogenic substrate were plotted against 
the different inhibitor concentrations to obtain IC50 
values using Equation 1 (Eq. 1), where A [I ] is the 
enzyme activity with inhibitor concentration [I ]; and 
A[0] is the enzyme activity without interference from an 
inhibitor:
A[I] = A[0] × {1 – [[I]/([I] + IC50)]}                  (Eq. 1)
Results
Anti-SARS-CoV activity of test extracts as measured 
by cell-based cytopathogenic effect (CPE) assay
The anti-SARS-CoV activity of test extracts was first 
measured using a cell-based assay of the cytopathogenic 
effect on infected Vero E6 cells as described previously 
(Wen et al., 2007). Figure 2, panel A, shows the original 
morphology of the Vero E6 cells without treatment with 
test extracts (negative control), and panel B shows the 
cytopathic morphology of SARS-CoV-infected Vero E6 
cells (positive control). Inhibition of SARS-CoV 
mediated CPE in Vero E6 cells was graded into three 
levels +, ++ and +++ (where + represented least 
inhibition, and +++ represented most inhibition) as 
shown in panels C, D, and E, respectively. Valinomycin 
(VAL), which has previously been reported to exhibit 
strong anti-SARS bioactivity in vitro (Wu et al., 2004), 
was employed as a reference control with high 
inhibition (level +++) (Table 1). Among all tested 
extracts, none of the W fractions from test plant 
materials conferred significant anti-SARS activity. For 
E, M and H fractions from all herbal extracts, only six 
extracts, CBE and CBM from Rhizoma Cibotii (狗脊 
gǒu jǐ; the dried rhizome of Cibotium barometz), GSH 
from Gentianae Radix (龍膽 lóng dǎn; the dried 
rhizome of Gentiana scabra), DBM from Dioscoreae 
Rhizoma (山藥 shān yào; the tuber of Dioscorea 
batatas), CTH from Cassiae Semen (決明子 jué míng zǐ; 
the dried seed of Cassia tora), and TCH from Loranthi 
Ramus (桑寄生 sāng jì shēng; the dried stem, with leaf 
of Taxillus chinensis) (designated as GSH, DBM, CTH 
and TCH, respectively), and two from showed inhibitory 
activities (at levels + to +++) in the CPE assays at 
Figure 2. Inhibition of cytopathogenic effect (CPE) of SARS-CoV-infected Vero E6 cells by TCM phytoextracts. Representative cell-culture 
phenotypes or behavior of Vero E6 cells with or without infection with SARS-CoV are shown in A and B, respectively. C, D, and E are 
semiquantitative representations of  the three levels of CPE inhibition (low +, moderate ++, and high +++), as revealed by phase contrast microscopy.
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concentrations between 25 and 200 μg/ml (Table 1). To 
evaluate whether the vehicle solvent (0.2 - 0.4% 
DMSO) can result in possible cytotoxic or negative 
effects on Vero E6 cells, MTT assay and microscopic 
examinations were performed. Our results showed little 
or no cytotoxic effect was detectable in 0.2-0.4% 
DMSO-treated cells, as in good agreement with our 
previous findings (Wen et al., 2007).
Inhibition of SARS-CoV replication evaluated using 
ELISA. 
To investigate whether the six herbal extracts that 
exhibited potent inhibitory activity could significantly 
inhibit viral replication, levels of spike protein in SARS-
CoV infected Vero E6 cells with or without treatment 
with test extracts, were measured by ELISA. As seen 
in Figure 3A the six extracts showed anti-SARS-CoV 
replication activities at concentrations of 0.1 - 10 μg/ml 
as detected by ELISA. The concentration of each test 
extract required to inhibit 50% of viral replication (EC50) 
was calculated and summarized in Table 2. In contrast to 
CBM which had EC50 values higher than 10 μg/ml, the 
EC50 values of CBE, GSH, DBM, CTH and TCH were 
determined at 8.42, 8.70, 8.06, 8.42 and, 5.39 μg/ml, 
respectively. Although these values are 2-3 fold higher 
than that of the reference compound valinomycin (VAL) 
(EC50 = 1.87 μg/ml), the considerably low EC50 values 
(< 10 μg/ml) of these extracts are very interesting, 
and may suggest that these test extracts apparently 
can significantly inhibit SARS-CoV replication with 
specificities. 
Cytotoxic effects of test extracts on Vero E6 Cells. 
Since it is possible that the anti-SARS-CoV activity 
of the test extracts may result from a direct inhibition on 
the growth of test Vero E6 cells, MTT assay was thus 
conducted to evaluate potential cytotoxic effect of test 
phytoextracts in concentrations ranging from 10 to 500 
μg/ml on Vero E6 cells. As seen in Table 2 and Figure 
Figure 3. Inhibitory effect of test extracts on replication of SARS-
CoV and on proliferation of Vero E6 cells. (A) Inhibition of SARS-
CoV replication in response to treatment with specific extracts is 
measured by the level of SARS-CoV spike protein (SARS-CoV S) 
in test Vero E6 cell cultures using ELISA. % of Control = (OD492 of 
SARS-CoV infection – OD492 of mock infection [concn X]) / (OD492 
of SARS-CoV infection – OD492 of Mock infection [concn 0]). (B) 
Cytotoxic effects of test extracts on Vero E6 cells were determined 
using MTT assay. Each data point represents the mean ± SD (n = 3). 
Cell viability (%) = (OD570 of treated cells / OD570 of vehicle cells) × 
100.
Table 2. Effect of test extracts on Vero E6 cell proliferation and 
SARS-CoV replication
Sample CC50 (μg/ml)a EC50 (μg/ml)b Selective Indexc
CBE >500 8.42 >59.4
CBM >500 >10 N.C d
GSH >500 8.70 >57.5
DBM >500 8.06 >62.0
CTH >500 8.43 >59.3
TCH >500 5.39 >92.8
VAL e 75.01 1.81 41.4
a  Determined as the cytotoxic concentration of test extracts that 
reduced cell viability to 50% of the control (i.e., cells with a treated 
equal volume of vehicle control). Each value was calculated with 
data obtained from triplicate samples.
b  Determined as the effective concentration at which inhibition of 
viral replication was reduced to 50% of the untreated (control) cell 
cultures. Each value was calculated with data obtained from triplicate 
samples.
c  Selective index was taken to be the ratio of CC50 to EC50 (CC50/EC50)
d N.C., not calculable
e VAL., valinomycin
Table 1. Effect of Traditional Chinese Medicine extracts on 
cytopathogenic effect (CPE) of SARS-CoV on Vero E6 cells
Sample
Extract Concentration (μg/ml)
code 200 100 50 25 0
Rhizoma Cibotii ( 狗脊 gǒu jǐ) CBE +++ ++ + + —
Rhizoma Cibotii ( 狗脊 gǒu jǐ) CBM +++ + + — —
Gentianae Radix ( 龍膽 lóng dǎn) GSH +++ ++ + + —
Dioscoreae Rhizoma ( 山藥 shān yào) DBM +++ ++ + + —
Cassiae Semen ( 決明子 jué míng zǐ) CTH ++ ++ + + —
Loranthi Ramus ( 桑寄生 sāng jì shēng) TCH +++ +++ ++ + —
Valinomycin VAL N.T. N.T. N.T. +++ —
a N.T., not tested
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3B, the cytotoxic concentrations of individual extracts 
that reduced the cell viability to 50% of the untreated 
control (CC50) were calculated and compared with each 
other. The CC50 values for all test extracts were detected 
to be higher than 500 μg/ml; interestingly, however, 
the positive control valinomycin had in fact a relatively 
low CC50 value (75.01 μg/ml). This result suggests 
that these extracts had little or no interference with the 
growth of Vero E6 cells, and they can be considered as 
generally biologically safe to the host cells. According 
to the results in Table 2, we hence suggest that it is 
quite unlikely that the inhibitory effects detected for 
the tested herbal extracts on viral replication of SARS-
CoV were due to the inhibitory effect on cell growth or 
viability of host cells. In addition, the selective index 
(SI), the ratio of CC50 to EC50, was also then calculated 
to evaluate the potency of anti-SARS-CoV activity of 
test extracts (Table 2). The SI values of CBE, CBM, 
GSH, DBM, CTH and TCH were determined at the 
value of > 59.4, not calculable, > 57.5, > 62.1, > 59.4, 
and > 92.9, respectively. These SI values, with the 
exception of CBM, are all higher than the value of the 
reference control valinomycin (SI = 41.4) as determined 
in parallel in this study and as we previously reported 
(Wu et al., 2004).
Inhibitory effects of test extracts on SARS-CoV 3CL 
protease activity. 
The proteolytic cleavage of viral polyproteins at 
specific sites by 3CL protease plays an important role 
in SARS-CoV replication (Chen et al., 2002; Kuo et 
al., 2004). To understand whether the anti-SARS-CoV 
activity of these extracts can result from inhibition of 
SARS-CoV 3CL protease activity, all six test extracts 
were further evaluated in a 3CL protease inhibition 
assay. The IC50 values of extracts were measured using a 
quenched fluorescence energy transfer (FRET) method 
as previously described (Kuo et al., 2004). Niclosamide 
(NIC) has been reported to be an inhibitor of SARS-
CoV 3CL protease activity and was used as a reference 
control: NIC had an IC50 value of 13 μg/ml in this study. 
As seen in Figure 4 and Table 3, among these extracts 
tested, only CBM and DBM conferred a considerable 
inhibition of SARS-CoV 3CL protease activity, with 
IC50 values of 39 μg/ml and 44 μg/ml, respectively. The 
IC50 values of the other test extracts were all higher than 
50 μg/ml.
Figure 4. Inhibition of the enzymatic activity of SARS-CoV 3CL 
protease by CBM and DBM. The initial velocities of the inhibitory 
activities on 50 nM SARS 3CL-protease using 6 μM fluorogenic 
substrate were plotted against the different inhibitor concentrations 
(0 – 0.08 mg/ml) of CBM (A) and DBM (B) to obtain the IC50 values 
using Eq. 1, as described in Materials and Methods.
Table 3. IC50 values of test extracts on the enzymatic activities of 
SARS-CoV 3CL protease
Sample IC50 (μg/ml)
CBE >50
CBM 39 ± 3
GSH >50
DBM 44 ± 2
CTH >50
TCH >50
NIC a 13. ± 0.7
a NIC, niclosamide
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Since the outbreak of SARS in 2003, considerable 
effort has been put into research of the disease; however, 
to date, no drug has been approved for potential future 
clinical use in patients with SARS (Cleri et al., 2010). 
To assure adequate public safety and control of infection 
in the event of a re-emergence of this illness, effective 
anti-SARS-CoV agents may still be highly desirable or 
even necessary. Plant materials, especially for those that 
were previously used in traditional Chinese medicines, 
we believe are rich resources for development of the 
related therapeutic agents or drug candidates. In this 
study, we have employed a cell-based cytopathogenic 
effect (CPE) assay in SARS-CoV-infected Vero E6 
cells for screening more than 200 extracts for candidate 
anti-SARS-CoV activity. Six herbal extracts from 
traditional Chinese medicinal herbs were found to 
exhibit significant levels (+ to +++) of anti-SARS-CoV 
activity at concentrations of 25 and 100 μg/ml (Table 
1). As measured and compared by results from the CPE 
assays, this level of anti-SARS-CoV activity is better 
than that reported for glycyrrhizin (Cinatl et al., 2003), 
a compound with known anti-SARS-CoV activity, and 
extracts of other traditional herbs previously reported to 
confer anti-SARS-CoV activity (Lau et al., 2008; Li et 
al., 2005).
The CPE of viral infection may involve complex 
interactions of a number of molecular mechanisms 
between the SARS-CoV and test Vero E6 cells (Stadler 
et al., 2003). By quantification of the amount of spike 
protein present in SARS-CoV-infected Vero E6 cells 
(EC50), we showed that the anti-SARS-CoV activity of 
these extracts may act specifically on the inhibition of 
viral replication (Table 2 and Figure 3A). In addition, 
a MTT assay was adopted to determine the CC50 of test 
extracts, and our data led us to suggest that the anti-
viral activities we detected were apparently not due to 
the effects of cytotoxicity of test extracts on the host 
cells, as evidenced by the low EC50 of the extracts. The 
selective index (SI) value was calculated as the ratio 
of CC50 to EC50 as an indicator of the potency of test 
phytoextracts. In comparison to the positive control, 
valinomycin (VAL) (Wu et al., 2004), CBE, GSH, 
DBM, CTH and TCH showed potent activities against 
CPE, and they also exhibited marked inhibitory effects 
on SARS-CoV replication. The SI values (Table 2) for 
these five bioactive extracts are significantly higher even 
than the SI value of the positive control valinomycin (SI 
= 41.4). The SI values (all > 55) of these five extracts 
are also higher than two other traditional Chinese herbs 
previously reported to inhibit SARS-CoV infection; 
Cinnamomi cortex  was shown to inhibit SARS-CoV 
infection at a SI value of 23.4, and Toona sinensis 
extract was shown to inhibit SARS-CoV replication 
with an SI value of (12 to 17) (Chen et al., 2008). 
Taken together, we hence suggest that the six TCM 
phytoextracts reported here can inhibit SARS-CoV 
replication with little or no cytotoxicity to Vero E6 cells, 
and are may thus serve as useful candidates for future 
development of anti-SARS therapeutics. 
The SARS-CoV 3CL protease is involved in the 
viral maturation process by cleaving the virus-encoded 
polyproteins (Chen et al., 2002). Because of its pivotal 
role in the SARS-CoV life cycle, the 3CL protease 
is recognized as an important target for discovery of 
anti-SARS-CoV agents. Among the extracts tested for 
inhibition of SARS-CoV 3CL protease activity, the IC50 
values of CBM (39 μg/ml) and DBM (44 μg/ml) suggest 
that these two extracts can exhibit significant inhibitory 
activity against 3CL protease. A number of studies have 
contributed to the identification of inhibitors of SARS-
CoV 3CL protease [15, 28-29]. However, the IC50 
values of CBM and DBM for inhibition of SARS-CoV 
3CL protease are also similar or higher than extracts 
from other anti-SARS-CoV medicinal herbs reported 
to date, including Isatis indigotica (IC50 = 53.8 μg/ml) 
(Li et al., 2005), Torreya nucifera (IC50 = 100 μg/ml), 
tea extract (IC50 = 125 μg/ml) (Chen et al., 2005) and 
Houttuynia cordata  (IC50 = 1000 μg/ml) (Lau et al., 
2008). We therefore suggest that the herbal extracts of 
CBM and DBM may be useful drug candidates against 
SARS-CoV 3CL protease and may have potential for 
use as alternative herbal therapies against SARS. The 
other four herbal extracts we tested other than these two 
herbal extracts may inhibit SARS-CoV replication via 
different working mechanisms including blocking of 
viral binding, inhibition of SARS-CoV fusion with the 
host cells, inhibition on activity of other SARS-CoV 
proteases and inhibition of RNA transcription (Kliger et 
al., 2005).
Recently, phytochemicals or extracts derived from 
traditionally used medicinal plants or herbs have been 
contemplated or clinically evaluated as alternative 
or complementary treatments for various diseases. 
Previous reports showed that Cibotium barometz 
inhibited osteoclast formation and has antioxidative, 
tyrosinase inhibiting and antibacterial activities 
(Cuong et al., 2009; Lai et al., 2009). In this study, 
Cibotium barometz  was found to possess good anti-
SAR-CoV activity and effectively inhibit SARS 3CL 
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protease activity. The bioactive components responsible 
for these activities should therefore warrant further 
investigations. Gentiana scabra  has previously been 
shown to confer a hepatoprotective effect (Jiang and 
Xue, 2005) and contains triterpenoids of secoiridoid 
and its glycosides (Chueh et al., 2001; Kakuda et 
al., 2001; Kim et al., 2009). Based on our previous 
study on anti-SARS-CoV phytocompounds (Wen et 
al., 2007), specific triterpenoids have been shown to 
inhibit SARS-CoV replication. We therefore suggest 
here that secoiridoid and its glycosides may contribute 
to the anti-SARS activity detected for Gentiana scabra 
extract , and secoiridoid and its glycosiedes may have 
potential for further evaluation as anti-SARS lead 
compounds. In our previous study (Su et al., 2011; Su 
et al., 2008), two specific polysaccharide-containing 
fractions from Dioscorea batatas tuber extracts 
significantly increased GM-CSF promoter activity in 
normal and inflamed skin, enhanced murine splenocyte 
proliferation ex vivo  and improved regeneration of 
bone marrow cells in vivo . Other studies also revealed 
that the ethanolic extract from Dioscorea batatas  can 
exert anti-inflammatory effect through the inhibition of 
NF-κB-mediated iNOS and COX-2 expressions (Jin et 
al., 2010). Interference of cyclooxygenase-2 (COX-2) 
expression may be correlated with anti-SARS-CoV 
and other antiviral activities (Amici et al., 2006; Kim 
et al., 2010). We therefore hypothesize that the anti-
SARS-CoV activities we demonstrated here may result 
from inhibition of COX-2 activity. Cassia tora has been 
found to confer anti-hypertensive (Hyun et al., 2009), 
anti-hyperlipidemia (Cho et al., 2007),  anti-bacterial 
(Hatano et al., 1999), and anti-fungal properties (Kim et 
al., 2004). Anthraquinones including emodin, physcion, 
and rhein may be the active phytocompounds that confer 
these activities (Kim et al., 2004; Wu and Yen, 2004). 
Because emodin has already been found to exhibit anti-
SARS-CoV activity via inhibition of the viral entry  by 
binding with the spike proteins and interfering with the 
SARS-CoV 3CL protease activity, we hypothesize that 
the active phytochemical components responsible for 
anti-SARS-CoV activity of CTH may be contributed 
by emodin or another anthraquinone(s) suggested 
or known to present in CTH. Taxillus chinensis  was 
shown to inhibit fatty acid synthase (Wang et al., 2008; 
Wang et al., 2006). Based on the previous study (Yi et 
al., 2004), which showed luteolin and quercetin can 
interfere with the entry of the virus to its host cells, 
we therefore hypothesize that specific glycosylated 
flavonoid and quercetin may play an effective role 
in this activity. Whether these flavonoids can also 
contribute to the detected anti-SARS activity warrants 
future investigation.
In summary, in this study we showed that six 
phytoextracts from Rhizoma Cibotii (狗脊 gǒu jǐ), 
Gentianae Radix (龍膽 lóng dǎn), Dioscoreae Rhizoma 
(山藥 shān yào), Cassiae Semen (決明子 jué míng 
zǐ), and Loranthi Ramus (桑寄生 sāng jì shēng;) can 
confer effective anti-SARS-CoV activity via inhibition 
of SARS-CoV replication. The CBM and DBM extracts 
also inhibited the 3CL protease activity of SARS-
CoV. These findings suggest that these phytoextracts 
studied as a TCM experience may be valued as a useful 
approach for future development of anti-SARS-CoV 
therapeutic agents.
Acknowledgement. We thank Ms Miranda Loney, 
Academia Sinica, for professional editing of this 
manuscript.
References
Amici, C., Di Coro, A., Ciucci, A., Chiappa, L., Castilletti, C., 
Martella, V., Decaro, N., Buonavoglia, C., Capobianchi, M.R., 
Santoro, M.G. 2006. Indomethacin has a potent antiviral activity 
against SARS coronavirus. Antiviral Therapy 11, 1021-1030.
Chen, C.J., Michaelis, M., Hsu, H.K., Tsai, C.C., Yang, K.D., Wu, 
Y.C., Cinatl, J., Jr., Doerr, H.W. 2008. Toona sinensis Roem tender 
leaf extract inhibits SARS coronavirus replication. Journal of 
Ethnopharmacology 120, 108-111.
Chen, C.N., Lin, C.P., Huang, K.K., Chen, W.C., Hsieh, H.P., Liang, 
P.H., Hsu, J.T., 2005. Inhibition of SARS-CoV 3C-like Protease 
Activity by Theaflavin-3,3'-digallate (TF3). Evidence-based 
Complementary and Alternative Medicine 2, 209-215.
Chen, Y.H., Chen, A.P., Chen, C.T., Wang, A.H., Liang, P.H., 
2002. Probing the conformational change of Escherichia coli 
undecaprenyl pyrophosphate synthase during catalysis using an 
inhibitor and tryptophan mutants. Journal of Biological Chemistry 
277, 7369-7376.
Cho, I.J., Lee, C., Ha, T.Y., 2007. Hypolipidemic effect of soluble 
fiber isolated from seeds of Cassia tora Linn. in rats fed a high-
cholesterol diet. Journal of Agricultural and Food Chemistry 55, 
1592-1596.
Chueh, F.S., Chen, C.C., Sagare, A.P., Tsay, H.S., 2001. Quantitative 
determination of secoiridoid glucosides in in vitro  propagated 
plants of Gentiana davidii var. formosana by high performance 
liquid chromatography. Planta Medica 67, 70-73.
Cinatl, J., Jr., Michaelis, M., Hoever, G., Preiser, W., Doerr, H.W., 
2005. Development of antiviral therapy for severe acute respiratory 
syndrome. Antiviral Research 66, 81-97.
Cinatl, J., Morgenstern, B., Bauer, G., Chandra, P., Rabenau, H., 
Doerr, H.W., 2003. Glycyrrhizin, an active component of liquorice 
roots, and replication of SARS-associated coronavirus. Lancet 
361, 2045-2046.
Cleri, D.J., Ricketti, A.J., Vernaleo, J.R., 2010. Severe acute respiratory 
syndrome (SARS). Infectious Disease Clinics of North America 
24, 175-202.
Cuong, N.X., Minh, C.V., Kiem, P.V., Huong, H.T., Ban, N.K., Nhiem, 
N.X., Tung, N.H., Jung, J.W., Kim, H.J., Kim, S.Y., Kim, J.A., 
Kim, Y.H., 2009. Inhibitors of osteoclast formation from rhizomes 
of Cibotium barometz. Journal of Natural Products. 72, 1673-1677.
De Clercq, E., 2004. Antivirals and antiviral strategies. Nature Reviews 

Wen et al . / Journal of Traditional and Complementary Medicine 1 (2011) 
Microbiology 2, 704-720.
Drosten, C., Gunther, S., Preiser, W., van der Werf, S., Brodt, H.R., 
Becker, S., Rabenau, H., Panning, M., Kolesnikova, L., Fouchier, 
R.A., Berger, A., Burguiere, A.M., Cinatl, J., Eickmann, M., 
Escriou, N., Grywna, K., Kramme, S., Manuguerra, J.C., Muller, 
S., Rickerts, V., Sturmer, M., Vieth, S., Klenk, H.D., Osterhaus, 
A.D., Schmitz, H., Doerr, H.W., 2003. Identification of a novel 
coronavirus in patients with severe acute respiratory syndrome. 
New England Journal of Medicine 348, 1967-1976.
Gallagher, T.M., Buchmeier, M.J., 2001. Coronavirus spike proteins in 
viral entry and pathogenesis. Virology 279, 371-374.
Groneberg, D.A., Poutanen, S.M., Low, D.E., Lode, H., Welte, T., 
Zabel, P., 2005. Treatment and vaccines for severe acute respiratory 
syndrome. Lancet Infectious Disease 5, 147-155.
Hatano, T., Uebayashi, H., Ito, H., Shiota, S., Tsuchiya, T., Yoshida, T., 
1999. Phenolic constituents of Cassia seeds and antibacterial effect 
of some naphthalenes and anthraquinones on methicillin-resistant 
Staphylococcus aureus. Chemical & Pharmaceutical Bulletin 
(Tokyo) 47, 1121-1127.
Hoever, G., Baltina, L., Michaelis, M., Kondratenko, R., Baltina, L., 
Tolstikov, G.A., Doerr, H.W., Cinatl, J. Jr., 2005. Antiviral activity 
of glycyrrhizic acid derivatives against SARS-coronavirus. Journal 
of Medicinal Chemistry 48, 1256-1259.
Holmes, K.V., 2003. SARS coronavirus: a new challenge for 
prevention and therapy. Journal of Clinical Investigation 111, 
1605-1609.
Hyun, S.K., Lee, H., Kang, S.S., Chung, H.Y., Choi, J.S., 2009. 
Inhibitory activities of Cassia tora and its anthraquinone 
constituents on angiotensin-converting enzyme. Phytotherapy 
Research 23, 178-184.
Jiang, W.X., Xue, B.Y,. 2005. Hepatoprotective effects of Gentiana 
scabra on the acute liver injuries in mice. Zhongguo Zhong Yao Za 
Zhi 30, 1105-1107.
Jin, M., Suh, S.J., Yang, J.H., Lu, Y., Kim, S.J., Kwon, S., Jo, T.H., 
Kim, J.W., Park, Y.I., Ahn, G.W., Lee, C.K., Kim, C.H., Son, 
J.K., Son, K.H., Chang, H.W., 2010. Anti-inflammatory activity 
of bark of Dioscorea batatas DECNE through the inhibition of 
iNOS and COX-2 expressions in RAW264.7 cells via NF-kappaB 
and ERK1/2 inactivation. Food and Chemical Toxicology 48, 
3073-3079.
Kakuda, R., Iijima, T., Yaoita, Y., Machida, K., Kikuchi, M., 2001. 
Secoiridoid glycosides from Gentiana scabra. Journal of Natural 
Products 64, 1574-1575.
Kim, H.Y., Eo, E.Y., Park, H., Kim, Y.C., Park, S., Shin, H.J., Kim, K., 
2010. Medicinal herbal extracts of Sophorae radix, Acanthopanacis 
cortex, Sanguisorbae radix and Torilis fructus inhibit coronavirus 
replication in vitro. Antiviral therapy 15, 697-709.
Kim, J.A., Son, N.S., Son, J.K., Jahng, Y., Chang, H.W., Jang, T.S., 
Na, M., Lee, S.H., 2009. Two new secoiridoid glycosides from 
the rhizomes of Gentiana scabra Bunge. Archives of Pharmacal 
Research 32, 863-867.
Kim, Y.M., Lee, C.H., Kim, H.G., Lee, H.S., 2004. Anthraquinones 
isolated from Cassia tora (Leguminosae) seed show an antifungal 
property against phytopathogenic fungi. Journal of Agricultural and 
Food Chemistry 52, 6096-6100.
Kliger, Y., Levanon, E.Y., Gerber, D., 2005. From genome to antivirals: 
SARS as a test tube. Drug Discovery Today 10, 345-352.
Ksiazek, T.G., Erdman, D., Goldsmith, C.S., Zaki, S.R., Peret, T., 
Emery, S., Tong, S., Urbani, C., Comer, J.A., Lim, W., Rollin, P.E., 
Dowell, S.F., Ling, A.E., Humphrey, C.D., Shieh, W.J., Guarner, 
J., Paddock, C.D., Rota, P., Fields, B., DeRisi, J., Yang, J.Y., Cox, 
N., Hughes, J.M., LeDuc, J.W., Bellini, W.J., Anderson, L.J., 2003. 
A novel coronavirus associated with severe acute respiratory 
syndrome. New England Journal of Medicine 348, 1953-1966.
Kuiken, T., Fouchier, R.A., Schutten, M., Rimmelzwaan, G.F., van 
Amerongen, G., van Riel, D., Laman, J.D., de Jong, T., van 
Doornum, G., Lim, W., Ling, A.E., Chan, P.K., Tam, J.S., Zambon, 
M.C., Gopal, R., Drosten, C., van der Werf, S., Escriou, N., 
Manuguerra, J.C., Stohr, K., Peiris, J.S., Osterhaus, A.D., 2003. 
Newly discovered coronavirus as the primary cause of severe acute 
respiratory syndrome. Lancet 362, 263-270.
Kuo, C.J., Chi, Y.H., Hsu, J.T., Liang, P.H., 2004. Characterization 
of SARS main protease and inhibitor assay using a fluorogenic 
substrate. Biochemical and Biophysical Research Communications 
318, 862-867.
Lai, H.Y., Lim, Y.Y., Tan, S.P., 2009. Antioxidative, tyrosinase 
inhibiting and antibacterial activities of leaf extracts from 
medicinal ferns. Bioscience Biotechnology & Biochemistry 73, 
1362-1366.
Lai, S.T., 2005. Treatment of severe acute respiratory syndrome. 
European Journal of Clinical Microbiology & Infectious Diseases 
24, 583-591.
Lau, K.M., Lee, K.M., Koon, C.M., Cheung, C.S., Lau, C.P., Ho, 
H.M., Lee, M.Y., Au, S.W., Cheng, C.H., Lau, C.B., Tsui, S.K., 
Wan, D.C., Waye, M.M., Wong, K.B., Wong, C.K., Lam, C.W., 
Leung, P.C., Fung, K.P., 2008. Immunomodulatory and anti-SARS 
activities of Houttuynia cordata. Journal of Ethnopharmacology 
118, 79-85.
Li, S.Y., Chen, C., Zhang, H.Q., Guo, H.Y., Wang, H., Wang, L., 
Zhang, X., Hua, S.N., Yu, J., Xiao, P.G., Li, R.S., Tan, X., 2005. 
Identification of natural compounds with antiviral activities against 
SARS-associated coronavirus. Antiviral Research 67, 18-23.
Lin, C.W., Tsai, F.J., Tsai, C.H., Lai, C.C., Wan, L., Ho, T.Y., Hsieh, 
C.C., Chao, P.D., 2005. Anti-SARS coronavirus 3C-like protease 
effects of Isatis indigotica root and plant-derived phenolic 
compounds. Antiviral Research 68, 36-42.
Peiris, J.S., Yuen, K.Y., Osterhaus, A.D., Stohr, K., 2003. The severe 
acute respiratory syndrome. New England Journal of Medicine 
349, 2431-2441.
Ryu, Y.B., Jeong, H.J., Kim, J.H., Kim, Y.M., Park, J.Y., Kim, D., 
Nguyen, T.T., Park, S.J., Chang, J.S., Park, K.H., Rho, M.C., Lee, 
W.S., 2010. Biflavonoids from Torreya nucifera displaying SARS-
CoV 3CL(pro) inhibition. Bioorganic & Medicinal Chemistry 18, 
7940-7947.
So, L.K., Lau, A.C., Yam, L.Y., Cheung, T.M., Poon, E., Yung, R.W., 
Yuen, K.Y., 2003. Development of a standard treatment protocol for 
severe acute respiratory syndrome. Lancet 361, 1615-1617.
Stadler, K., Masignani, V., Eickmann, M., Becker, S., Abrignani, S., 
Klenk, H.D., Rappuoli, R., 2003. SARS--beginning to understand a 
new virus. Nature Reviews Microbiology 1, 209-218.
Stroher, U., DiCaro, A., Li, Y., Strong, J.E., Aoki, F., Plummer, 
F., Jones, S.M., Feldmann, H., 2004. Severe acute respiratory 
syndrome-related coronavirus is inhibited by interferon- alpha. 
Journal of Infectious Diseases 189, 1164-1167.
Su, P.F., Li, C.J., Hsu, C.C., Benson, S., Wang, S.Y., Aravindaram, K., 
Chan, S.I., Wu, S.H., Yang, F.L., Huang, C.H., Shyur, L.F., Yang, 
N.S., 2011. Dioscorea phytocompounds enhance murine splenocyte 
proliferation ex vivo and improve regeneration of bone marrow 
cells in vivo. Evidence-Based Complementary and Alternative 
Medicine 2011, 1-11.
Su, P.F., Staniforth, V., Li, C.J., Wang, C.Y., Chiao, M.T., Wang, 
S.Y., Shyur, L.F., Yang, N.S., 2008. Immunomodulatory effects 
of phytocompounds characterized by in vivo transgenic human 
GM-CSF promoter activity in skin tissues. Journal of Biomedical 
Science 15, 813-822.
Tan, E.L., Ooi, E.E., Lin, C.Y., Tan, H.C., Ling, A.E., Lim, B., 
Stanton, L.W,. 2004. Inhibition of SARS coronavirus infection in 
vitro with clinically approved antiviral drugs. Emerging Infectious 
Disease 10, 581-586.
Wang, Y., Deng, M., Zhang, S.Y., Zhou, Z.K., Tian, W.X., 2008. 
Parasitic loranthus from Loranthaceae rather than Viscaceae 
potently inhibits fatty acid synthase and reduces body weight in 
mice. Journal of Ethnopharmacology 118, 473-478.
Wang, Y., Zhang, S.Y., Ma, X.F., Tian, W.X., 2006. Potent inhibition of 
fatty acid synthase by parasitic loranthus [Taxillus chinensis (dc.) 
danser] and its constituent avicularin. Journal of Enzyme Inhibition 
and Medicinal Chemistry 21, 87-93.
Wen, C.C., Kuo, Y.H., Jan, J.T., Liang, P.H., Wang, S.Y., Liu, H.G., 
Lee, C.K., Chang, S.T., Kuo, C.J., Lee, S.S., Hou, C.C., Hsiao, 
P.W., Chien, S.C., Shyur, L.F., Yang, N.S., 2007. Specific plant 

Wen et al . / Journal of Traditional and Complementary Medicine 1 (2011) 
terpenoids and lignoids possess potent antiviral activities against 
severe acute respiratory syndrome coronavirus. Journal of 
Medicinal Chemistry 50, 4087-4095.
Wu, C.H., Yen, G.C., 2004. Antigenotoxic properties of Cassia tea 
(Cassia tora L.): mechanism of action and the influence of roasting 
process. Life Science 76, 85-101.
Wu, C.Y., Jan, J.T., Ma, S.H., Kuo, C.J., Juan, H.F., Cheng, Y.S., Hsu, 
H.H., Huang, H.C., Wu, D., Brik, A., Liang, F.S., Liu, R.S., Fang, 
J.M., Chen, S.T., Liang, P.H., Wong, C.H., 2004. Small molecules 
targeting severe acute respiratory syndrome human coronavirus. 
Proceedings of the National Academy of Sciences of the United 
States of America 101, 10012-10017.
Yi, L., Li, Z., Yuan, K., Qu, X., Chen, J., Wang, G., Zhang, H., Luo, 
H., Zhu, L., Jiang, P., Chen, L., Shen, Y., Luo, M., Zuo, G., Hu, J., 
Duan, D., Nie, Y., Shi, X., Wang, W., Han, Y., Li, T., Liu, Y., Ding, 
M., Deng, H., Xu, X., 2004. Small molecules blocking the entry 
of severe acute respiratory syndrome coronavirus into host cells. 
Journal of Virology 78, 11334-11339.
